Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS

Objective: To investigate the impact of resveratrol on the metabolism of ibrutinib in vitro and in vivo. Methods: In vitro, rat liver microsomes (RLM) and human liver microsomes (HLM) were used to study. In vivo, 18 male SD rats were randomly divided into three groups (n = 6): ibrutinib and the multiple dose of 100 mg/kg resveratrol for consecutive 7 days (Group A), ibrutinib and the single dose of 100 mg/kg resveratrol (Group B), ibrutinib (Group C). Processed samples were analyzed by UPLC-MS/MS. Results: Resveratrol showed inhibition on RLM and HLM in vitro. The IC50 of resveratrol was 8.745 mu M in RLM and 7.789 mu M in HLM. Furthermore, Groups A and B both increased the AUC and reduced the CLz/F. The C-max of Group A and the MRT(0-t) of Group B were significantly improved. Conclusions: Resveratrol inhibits the pharmacokinetic of ibrutinib in vitro and in vivo. It is necessary to pay more attention to adjust the dose of the drug when resveratrol is used in combination with ibrutinib.